

ATTACH TO
#4

JC886 U.S. PTO
09/727369



11/29/00

Please type a plus sign (+) inside this box →

Approved for use through 10/31/99. GMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14-19B/FTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/121,114
Filing Date	12/10/00
First Named Inventor	DAVID YOUNG
Group Art Unit	1600
Examiner Name	

Attorney Docket Number 2056.007

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	TP
LAD		Badger CC, Bernstein ID. Prospects for monoclonal antibody therapy of leukemia and lymphoma. <i>Cancer</i> . Vol. 58. 1986. pp. 584-9.	
		Begg AC, Mooren E. Rapid fluorescence-based assay for radiosensitivity and chemosensitivity testing in mammalian cells <i>in vitro</i> . <i>Cancer Research</i> . Vol. 49. 1989. pp. 565-9.	
		Boven E, Pinedo HM. Monoclonal antibodies in cancer treatment: where do we stand after 10 years? <i>Radiotherapy & Oncology</i> . Vol. 5. 1986. pp. 109-17.	
		Costa A, Silvestrini R, Del Bino G, Motta R. Implications of disaggregation procedures on biological representation of human solid tumours. <i>Cell Tissue Kinet</i> . Vol. 20. 1987. pp. 171-80.	
		Dairkee SH, Paulo EC, Traquina P, Moore DH, Ljung BM, Smith HS. Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells. <i>Cancer Res</i> . Vol. 57. 1997. pp. 1590-6.	
		Dillman RO. Monoclonal antibodies for treating cancer. <i>Annals of Internal Medicine</i> . Vol. 111. 1989. pp. 592-603.	
		Dillman RO. Antibodies as cytotoxic therapy. <i>Journal of Clinical Oncology</i> . Vol. 12. 1994. pp. 1497-515.	
		Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. <i>Advances in Cancer Research</i> . Vol. 71. 1997. pp. 343-71.	
		Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. <i>Cancer Cells</i> . Vol. 3. 1991. pp. 77-85.	
✓		Engelholm SA, Spang-Thomsen M, Brunner N, Nohr I, Vindelov LL. Disaggregation of human solid tumours by combined mechanical and enzymatic methods. <i>Br J Cancer</i> . Vol. 51. 1985. pp. 93-6.	
LAD		Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. <i>Cancer Research</i> . Vol. 47. 1987. pp. 830-40.	

Examiner
Signature

Date
Considered

3/22/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →

PTO/SB/065 (10-06)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.*	Indicate name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T:
LRB	1	Fook KA. Biological therapy of cancer. <i>Breast Cancer Research & Treatment</i> . Vol. 7. 1986. pp. 5-14.	
J	2	Franzen B, Linder S, Okuzawa K, Kato H, Auer G. Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. <i>Electrophoresis</i> . Vol. 14. 1993. pp. 1045-53.	
J	3	Harris DT, Mastrangelo MJ. Serotherapy of cancer. <i>Seminars in Oncology</i> . Vol. 16. 1989. pp. 180-98.	
J	4	Holz E, Raab R, Rietmuller G. Antibody-based immunotherapeutic strategies in colorectal cancer. <i>Recent Results in Cancer Research</i> . Vol. 142. 1996. pp. 381-400.	
LRB	5	Kravtsov VD, Fabian I. Automated monitoring of apoptosis in suspension cell cultures. <i>Laboratory Investigation</i> . Vol. 74. 1996. pp. 557-70.	
	6		
	7		
	8		
	9		
	10		
	11		
	12		
	13		
	14		
	15		
	16		
	17		
	18		
	19		
	20		
	21		
	22		
	23		
	24		
	25		
	26		
	27		
	28		
	29		
	30		
	31		
	32		
	33		
	34		
	35		
	36		
	37		
	38		
	39		
	40		
	41		
	42		
	43		
	44		
	45		
	46		
	47		
	48		
	49		
	50		
	51		
	52		
	53		
	54		
	55		
	56		
	57		
	58		
	59		
	60		
	61		
	62		
	63		
	64		
	65		
	66		
	67		
	68		
	69		
	70		
	71		
	72		
	73		
	74		
	75		
	76		
	77		
	78		
	79		
	80		
	81		
	82		
	83		
	84		
	85		
	86		
	87		
	88		
	89		
	90		
	91		
	92		
	93		
	94		
	95		
	96		
	97		
	98		
	99		
	100		

Examiner Signature		Date Considered	5/22/01
-----------------------	---	--------------------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEF 636. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.